Tumor necrosis factor-? inhibitors in therapy for psoriatic arthritis
The paper presents the data available in the literature on the efficacy and tolerability of basic tumor necrosis factor α inhibitors (TNF α) etanercept, adalimumab, infliximab in the treatment of psoriatic arthritis (PsA) and their effects on the major manifestations of this disease - cutaneous and...
Main Authors: | Vladimir Vasilyevich Badokin, I A Troshkina, Yu L Korsakova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2010-12-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | http://mrj.ima-press.net/index.php/mrj/article/view/326 |
Similar Items
-
Tumor necrosis factor-? inhibitors in therapy for psoriatic arthritis
by: Vladimir Vasilyevich Badokin, et al.
Published: (2010-12-01) -
PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva
Published: (2016-07-01) -
Biological therapy in psoriatic arthritis patients with and without previous biologic experience
by: Michael Ruberson Ribeiro da Silva, et al.
Published: (2022-07-01) -
Tumor necrosis factor (TNF)-α gene +489 polymorphisms: association with psoriatic arthritis
by: G. Murdaca, et al.
Published: (2013-01-01) -
Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
by: Yan Song, et al.
Published: (2019-05-01)